Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Naïve T-cell Deficits at Diagnosis and after Chemotherapy Impair Cell Therapy Potential in Pediatric Cancers

10 Jan 2019

Abstract excerpt

Abstract Translational data on chimeric antigen receptor (CAR) T-cell trials indicate that the presence of naïve T cells in the premanufacture product is important to clinical response and persistence. In anticipation of developing CAR trials for other tumors, we investigated the T-cell distribution from children with solid tumors and lymphomas at diagnosis and after every cycle of chemotherapy. We found that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immune Cell Function and Interaction
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30630850
DOI: 10.1158/2159-8290.cd-18-1314

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Naïve T-cell Deficits at Diagnosis and after Chemotherapy Impair Cell Therapy Potential in Pediatric CancersPMID 30630850Read ↗

Early-phenotype CAR-T cells for the treatment of pediatric cancers.Semantic proximity Read ↗

Prior chemotherapy deteriorates T-cell quality for CAR T-cell therapy in B-cell non-Hodgkin’s lymphomaSemantic proximity Read ↗

Systems-level immunomonitoring in children with solid tumors to enable precision medicineSemantic proximity Read ↗

Evolving CAR T-Cell Therapy to Overcome the Barriers in Treating Pediatric Central Nervous System TumorsSemantic proximity Read ↗

Overcoming Antigen Escape and T-Cell Exhaustion in CAR-T Therapy for LeukemiaSemantic proximity Read ↗

A distinct CAR-T cell phenotype mediates therapeutic response at limited doses.Semantic proximity Read ↗

Children’s Oncology Group’s 2023 Blueprint for Research: Cellular Therapy and Stem Cell TransplantationSemantic proximity Read ↗

Common Trajectories of Highly Effective CD19-Specific CAR T Cells Identified by Endogenous T-cell Receptor LineagesSemantic proximity Read ↗

Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies.Semantic proximity Read ↗

Common trajectories of highly effective CD19-specific CAR T cells identified by endogenous T cell receptor lineagesSemantic proximity Read ↗

Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors: A Systematic Review and Meta-AnalysisSemantic proximity Read ↗

Single-cell profiling of CAR-T CD19 cell phenotypes and immune system dynamics in pediatric BCP-ALLSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.